GLOBAL BLOOD THERAPEUTICS Stock News

Equities research analysts expect that Global Blood Therapeutics, Inc. (NASDAQ:GBT) will report $55.29 million in sales for the current fiscal quarter, Zacks Investment Research reports. Twelve analysts have made estimates for Global Blood Therapeutics earnings, with estimates ranging from $53.00 million to $58.00 million. Global Blood Therapeutics posted sales of $41.30 million in the same []

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021, at 11:45 a.m. ET.

AQR Capital Management LLC raised its holdings in Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 130.1% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,080 shares of the companys stock after buying an additional 7,396 shares during the period. AQR Capital Management LLCs holdings []

Wall Street analysts forecast that Global Blood Therapeutics, Inc. (NASDAQ:GBT) will report sales of $55.29 million for the current fiscal quarter, according to Zacks. Twelve analysts have provided estimates for Global Blood Therapeutics earnings. The lowest sales estimate is $53.00 million and the highest is $58.00 million. Global Blood Therapeutics posted sales of $41.30 million []

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Analysts at Truist Securiti boosted their FY2021 earnings per share estimates for shares of Global Blood Therapeutics in a research note issued on Sunday, November 14th. Truist Securiti analyst J. Lee now anticipates that the company will post earnings of ($4.61) per share for the year, up from their []

Renaissance Technologies LLC purchased a new position in Global Blood Therapeutics, Inc. (NASDAQ:GBT) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 50,680 shares of the companys stock, valued at approximately $1,775,000. Renaissance Technologies LLC owned 0.08% of Global Blood Therapeutics as of []

Weiss Multi Strategy Advisers LLC boosted its position in shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 36.9% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 22,000 shares of the companys stock after acquiring an additional 5,927 shares during the quarter. Weiss Multi Strategy Advisers LLCs holdings in Global Blood Therapeutics were worth []

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Stifel 20

Global Blood (GBT) reports wider-than-expected loss in the third quarter of 2021 while its revenues miss estimates.

Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q3 2021 Results - Earnings Call Transcript

Global Blood (GBT) delivered earnings and revenue surprises of -2.73% and -3.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Today, we put rare disease concern, Global Blood Therapeutics, in the spotlight. The company has an approved product for Sickle Cell Disease that is looking to become a standard of care, but the initi

Jefferies initiated coverage of Global Blood Therapeutics Inc (NASDAQ: GBT) with a Buy rating and $68 price target. The analyst sees an upside of almost 145%.

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on October 1, 2021, the compensation committee of GBT's boa

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Cantor G